YooYoung Pharmaceutical
YooYoung Pharmaceutical is a Korean specialty pharmaceutical and medical device manufacturer (founded 1981) producing osteoarthritis injections, hyaluronic acid dermal fillers, and a world-first ALS stem cell therapy for domestic healthcare providers, international distributors, and CMO clients.
- Company typePrivate
- Founded1981
- HeadquartersSeoul, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What YooYoung Pharmaceutical does
YooYoung Pharmaceutical (유영제약, founded 1981) is a privately held Korean specialty pharmaceutical and medical device manufacturer headquartered in Seoul with primary manufacturing operations in Jincheon, Chungcheongbuk-do. The company develops, manufactures, and commercializes finished pharmaceutical products — oral solid dosages, prefilled syringes, ampoule injections — and hyaluronic acid-based medical devices, with portfolio focus on osteoarthritis treatments (Resyno-one, Atri, Atriplus), aesthetic medicine (DivaViva dermal filler series), chronic disease (Lucalo for constipation, Pravafenix for hyperlipidemia), and cell therapy (NeuroNata-R, the world's first approved stem cell treatment for ALS, co-developed with Corestem). Manufacturing is anchored by an EU-GMP compliant Jincheon facility with annual capacity of 800 million tablets, 25 million ampoules, and 15 million prefilled syringes, and the company holds a dense stack of regulatory certifications including KGMP, Japan PMDA GMP, CE Mark, ISO 13485, PIC/S GMP, BGMP, Kenya PPB GMP, and Taiwan TFDA QSD.
The company operates a hybrid revenue model combining direct domestic sales to Korean healthcare providers (hospitals, clinics, pharmacies), multi-jurisdiction exports (USD 10M+ annually across Japan, Asia, Europe, South America, and more recently China and Spain), exclusive distribution partnerships (notably Atriplus in the EU), licensing-in and licensing-out royalty arrangements (Pravafenix, BEMFOLA, SIMDAX, NS-126), and contract manufacturing (CMO) services for solid formulations and prefilled syringes to third-party pharmaceutical companies. Customer base is structurally diversified across domestic healthcare, international distributors, CMO clients, and end patients. Growth has been supported by progressive export expansion (USD 1M in 2009 → USD 10M in 2021 Export Tower awards), facility expansion (2007 EU-GMP 2nd factory, 2022 PFS line, 2023 storage facility), and a five-asset R&D pipeline targeting hyperlipidemia, anti-diabetic, skin booster, and osteoarthritis cell therapy indications. The company is family-controlled, with the second-generation CEO Jupyong Yoo assuming leadership in 2023, and remains privately held with no disclosed institutional investor or funding round activity.
YooYoung Pharmaceutical firmographics
Firmographics- Name
- YooYoung Pharmaceutical
- Legal name
- (주)유영제약
- Website
- https://yypharm.co.kr
- Company type
- Private
- Founded year
- 1981
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- YooYoung Pharmaceutical is a Korean specialty pharmaceutical and medical device manufacturer (founded 1981) producing osteoarthritis injections, hyaluronic acid dermal fillers, and a world-first ALS stem cell therapy for domestic healthcare providers, international distributors, and CMO clients.
- Ownership category
- akta.pro rank
YooYoung Pharmaceutical industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Oral Solid Dose (OSD) Generics (HLAIABAD)
Keywords
Where YooYoung Pharmaceutical is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
YooYoung Pharmaceutical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Manufacturing and selling of finished drug products including oral solid dosage (OSD) tablets, prefilled syringes, ampoules for injections, and specialty generic medications. Revenue is generated through domestic sales to healthcare providers and international exports to Japan, Asia, Europe, and South America.
- Licensing and Technology Transfer: Revenue from licensing agreements for proprietary technologies and products, including license-out agreements for products like Pravafenix, BEMFOLA, and SIMDAX, as well as license-in arrangements for new drug development.
- Medical Device Sales: Sales of hyaluronic acid-based medical devices including dermal fillers (DivaViva series) and injectable treatments for osteoarthritis.
- Contract Manufacturing (CMO): Contract manufacturing services offered to other pharmaceutical companies for solid formulations (uncoated tablets, coated tablets, hard capsules) and prefilled syringe formulations (1, 3, 5 mL).
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
YooYoung Pharmaceutical product offering
Product offeringCore offering
YooYoung Pharmaceutical manufactures and sells finished pharmaceutical products including oral solid dosage (OSD) tablets, prefilled syringes, and ampoule injections at its EU-GMP compliant Jincheon facility. The company also produces hyaluronic acid-based medical devices such as dermal fillers (DivaViva series) and arthritis injection treatments (Atri/Atriplus), and offers contract manufacturing (CMO) services for solid formulations and prefilled syringes to other pharmaceutical companies.
Product overview
YooYoung Pharmaceutical is a Korean pharmaceutical company offering a diversified portfolio of prescription drugs and medical devices. The company manufactures finished drug products including oral solid dosages, prefilled syringes, and ampoule injections at its KGMP-certified Jincheon factory. Key products include innovative new drugs (Resyno-one for osteoarthritis, NeuroNata-R for ALS as world's first stem cell treatment), hyaluronic acid-based medical devices (DivaViva filler series, Atri/Atri Plus for arthritis), and specialty generic medications. The R&D pipeline focuses on hyperlipidemia, anti-diabetic treatments, skin boosters, and cell therapies for osteoarthritis.
Differentiator
Problem solved
Functional benefit
Brands
- DivaViva: Dermal HA Filler series - independently developed and clinically completed dermal hyaluronic acid filler for wrinkle improvement
- NeuroNata-R
- Resyno-one (레시노원주)
- Atri (아트리)
Products and services
- Resyno-one Injection (레시노원주) Novel single-use injection for the treatment of hip osteoarthritis, developed as an innovative new drug by YooYoung Pharmaceutical.
- NeuroNata-R (뉴로나타-알주) World's first stem cell treatment for Amyotrophic Lateral Sclerosis (Lou Gehrig's disease), co-developed with Corestem and marketed as a treatment for rare neurodegenerative disease.
- DivaViva Series (디바비바 시리즈) Independently developed dermal hyaluronic acid filler series for wrinkle improvement and aesthetic/cosmetic medical applications, part of the Health & Beauty product line.
- Atri / Atriplus Injection (아트리/아트리플러스주) Hyaluronic acid-based arthritis treatment injection with CE Mark certification for the European market and exclusive EU sales partnership.
- Lucalo Tablets (루칼로정) Oral chronic constipation treatment medication launched for the domestic Korean market.
- Pravafenix Capsule (프라바페닉스캡슐) Hyperlipidemia combination product licensed from SMB (Laboratorios SMB) for distribution in the Korean market.
- Yooridion Injection (유리디온주) Injectable pharmaceutical product launched as part of the company's injectables portfolio.
- Pioda Tablets (피오다정) Oral solid dosage pharmaceutical product launched in 2024 as part of the company's OSD portfolio.
- Contract Manufacturing (CMO) Services Contract manufacturing services for pharmaceutical companies covering solid formulations (uncoated tablets, coated tablets, hard capsules) and prefilled syringe formulations (1, 3, 5 mL) at the EU-GMP certified Jincheon facility.
Quantifiable outcome
- Revenue surpassed KRW 100 billion in 2019
- +2 more outcomes
Companies that use YooYoung Pharmaceutical
Customer profileSegments4 records
Ideal customer profiles4 records
YooYoung Pharmaceutical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
YooYoung Pharmaceutical partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered strategic, core and minor.
- NovozymestrategicTechnology license-in contract for development of YY1201 enzyme-based pharmaceutical product.
- National Onco VenturecoreTechnology transfer contract for YYB-101 antibody novelty medication for cancer treatment development.
- European Distributor (EU)strategicExclusive sales contract for Atriplus injection in European (EU) regions, marking Yooyoung's expansion into European pharmaceutical markets.
- CorestemcorePartnership for co-research and licensure of stem cell treatment for Lou Gehrig's disease (ALS), resulting in the world's first stem cell therapy NeuroNata-R launched in 2015. This partnership positioned Yooyoung as a pioneer in cell therapy for rare diseases.
- SMB (Laboratorios SMB)strategicLicense agreement for Pravafenix (hyperlipidemia combination product) enabling international distribution of specialty generic product.
- Nippon Shinyaku (Japan)strategicLicense contract for allergic rhinitis treatment medication NS-126 with Japanese pharmaceutical company Nippon Shinyaku.
- Markit (주)마크잇minorWebsite development and operations (maintenance/repair) partner. Website development and management services commissioned to external professional company.
Scale indicators8 records
Recent moves12 records
Expansion highlights6 records
YooYoung Pharmaceutical competitors and assessment
Company assessmentBroad incumbents
- Dong-A Pharmaceutical: Established Korean pharma with a broad finished-drug product portfolio (OSD, injectables, biologics) and growing overseas operations — comparable category breadth but larger and more diversified.
- AbbVie (Allergan Aesthetics): Global leader in HA-based dermal fillers (Juvéderm) and aesthetics — competes with YooYoung's DivaViva series in international aesthetics markets and sets the bar for clinical and regulatory depth.
- Hanmi Pharmaceutical: Larger Korean pharma with global licensing-out expertise and a broad OSD/injectable pipeline — comparable GTM model (in/out-licensing, global partnerships) but operating at significantly greater scale.
- Galderma: Global dermatology and aesthetics company with leading HA filler franchises (Restylane, Emervel) — directly competes with YooYoung's HA fillers in regulated export markets and represents the global benchmark.
Direct peers
- Medytox: Korean aesthetics biotech specializing in botulinum toxin and HA-based injectable products — a direct competitor in the same HA filler and injectable aesthetics category as YooYoung's DivaViva.
- Ildong Pharmaceutical: Korean pharma of similar vintage producing finished drug products across OSD, injectables, and OTC segments with comparable manufacturing scale and export presence.
- Corestem: Korean biotech that co-developed and supplies NeuroNata-R (ALS stem cell therapy) with YooYoung. A closely linked therapeutic-area peer in stem cell therapy for degenerative disease.
- JW Pharmaceutical: Korean mid-sized pharma with OSD, injectable, and specialty drug manufacturing — similar product mix, GMP-certified facilities, and export orientation.
- Hugel: Korean specialty pharma with overlapping HA filler (TheChae/Wellage) and botulinum toxin aesthetics portfolios, plus injectable therapeutics — a closely comparable Korean peer in both aesthetics and injectable pharma.
- Daewoong Pharmaceutical: Mid-to-large Korean pharma with a diversified OSD, injectable, and aesthetics portfolio including Nabota (botulinum toxin) — directly comparable in business model, manufacturing footprint, and export-driven GTM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
YooYoung Pharmaceutical social profiles
Digital presenceYooYoung Pharmaceutical compliance and trust
Trust signalCompliance10 records
YooYoung Pharmaceutical financial estimates
Financial estimateRevenue estimate
Valuation estimate
YooYoung Pharmaceutical leadership team
Management profileNumber of profiles
Profiles3 records
YooYoung Pharmaceutical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
YooYoung Pharmaceutical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about YooYoung Pharmaceutical
What does YooYoung Pharmaceutical do?
YooYoung Pharmaceutical manufactures and sells finished pharmaceutical products including oral solid dosage (OSD) tablets, prefilled syringes, and ampoule injections at its EU-GMP compliant Jincheon facility. The company also produces hyaluronic acid-based medical devices such as dermal fillers (DivaViva series) and arthritis injection treatments (Atri/Atriplus), and offers contract manufacturing (CMO) services for solid formulations and prefilled syringes to other pharmaceutical companies.
Is YooYoung Pharmaceutical a public or private company?
YooYoung Pharmaceutical is a private company. It is classified as family owned and is currently operating.
When was YooYoung Pharmaceutical founded?
YooYoung Pharmaceutical was founded in 1981. It employs 51 to 100 people.
Where is YooYoung Pharmaceutical based?
YooYoung Pharmaceutical is headquartered in Seoul, South Korea, in the Asia region.
How does YooYoung Pharmaceutical make money?
Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Technology Transfer, medical Device Sales and contract Manufacturing (CMO).
Who are YooYoung Pharmaceutical's main competitors?
Broad incumbents on record are Dong-A Pharmaceutical, AbbVie (Allergan Aesthetics), Hanmi Pharmaceutical and Galderma. Direct peers are Medytox, Ildong Pharmaceutical, Corestem, JW Pharmaceutical, Hugel and Daewoong Pharmaceutical.
Does YooYoung Pharmaceutical have an API?
No public API is recorded for YooYoung Pharmaceutical.
What industry is YooYoung Pharmaceutical in?
YooYoung Pharmaceutical's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.